There are several SMO inhibitors currently in use or undergoing clinical trials:
Vismodegib (Erivedge): Approved for advanced BCC. Sonidegib (Odomzo): Another approved drug for advanced BCC. Glasdegib: Approved for use in combination with low-dose cytarabine in acute myeloid leukemia (AML).